Merck & Cie

Merck Patent Gmbh

Biomarin Pharmaceutical Inc.

Merck Eprova Ag

Eprova Ag

Mereck & Cie

Viola Groehn

Rudolf Moser

Fritz Blatter

Thomas Egger

Martin Szelagiewicz

Simon Mensah Ametamey

Ruth Boehni Stamm

Roger Schibli

Thomas Ammann

Tobias Ludwig Ross

Emil D Kakkis

Fredric D Price

Alejandro Dorenbaum

Daniel I Oppenheimer

Markus Ruettimann

Cristina Magdalena Muller

Michael Wilhelm Platscher

Marco Silvio Passafaro

Finn Bauer

Giuseppe Lapadula

Cindy Ramona Fischer

Raymond Behrendt

Simone Rachel Hoertner

Hans R Muller

Cristina Magdalena Mueller

Pierre Martin

Benoit Pugin

Andreas Schumacher

Dirk Spielvogel

Thomas Leighton Mindt

Harriet Struthers

Phoebe Lam

Thomas Betzel

Cristina Mueller

Silvan Boss

Simon Ametamey

Cristina Magdalena MÜLLER

The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters

The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.

Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed towards isomerically pureF-labelled (6S)- or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by anF-labelled N-heterocycle, for use in diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or inflammatory and autoimmune diseases and therapy thereof.

Isomerically pureF-labelled tetrahydrofolates

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.

Targeting aminoacid lipids

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed to stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof and a dicarboxylic acid, or a salt thereof, as well as, a processes of obtaining the same, and the use of such products.

Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.

The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising

Crystalline binary sodium salts of 5-methyl-(6S)-tetrahydrofolic acid with organic bases

Growing community of inventors

Dachsen, Switzerland

Viola Groehn